Recent advances in developing therapeutics for cystic fibrosis
Open Access
- 1 August 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 27 (R2) , R173-R186
Abstract
Despite hope that a cure was imminent when the causative gene was cloned nearly 30 years ago, cystic fibrosis (CF [MIM: 219700]) remains a life-shortening disease affecting more than 70 000 individuals worldwide. However, within the last 6 years the Food and Drug Administration's approval of Ivacaftor, the first drug that corrects the defective cystic fibrosis transmembrane conductance regulator protein [CFTR (MIM: 602421)] in patients with the G551D mutation, marks a watershed in the development of novel therapeutics for this devastating disease. Here we review recent progress in diverse research areas, which all focus on curing CF at the genetic, biochemical or physiological level. In the near future it seems probable that development of mutation-specific therapies will be the focus, since it is unlikely that any one approach will be efficient in correcting the more than 2000 disease-associated variants. We discuss the new drugs and combinations of drugs that either enhance delivery of misfolded CFTR protein to the cell membrane, where it functions as an ion channel, or that activate channel opening. Next we consider approaches to correct the causative genetic lesion at the DNA or RNA level, through repressing stop mutations and nonsense-mediated decay, modulating splice mutations, fixing errors by gene editing or using novel routes to gene replacement. Finally, we explore how modifier genes, loci elsewhere in the genome that modify CF disease severity, may be used to restore a normal phenotype. Progress in all of these areas has been dramatic, generating enthusiasm that CF may soon become a broadly treatable disease.Keywords
Funding Information
- Canadian Institutes of Health Research (CIHR MOP 258916)
- Cystic Fibrosis Canada (CFC; #2626)
- Genome Canada through the Ontario Genomics Institute (2018-OGI)
- Cystic Fibrosis Foundation (STRUG17PO)
- Cystic Fibrosis Foundation (Harris14G0, Harris 16G0, 17XX0)
- National Institutes of Health (R01HL094585, R01HD068901, R01HL117843)
This publication has 116 references indexed in Scilit:
- Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic FibrosisMolecular Therapy Nucleic Acids, 2013
- Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosisNature Genetics, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2Nature Genetics, 2011
- Pancreatic Bicarbonate Secretion Involves Two Proton PumpsJournal of Biological Chemistry, 2011
- Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteasesPflügers Archiv - European Journal of Physiology, 2010
- Intronic enhancers coordinate epithelial-specific looping of the active CFTR locusProceedings of the National Academy of Sciences, 2009
- Slc26a9 Is Inhibited by the R-region of the Cystic Fibrosis Transmembrane Conductance Regulator via the STAS DomainJournal of Biological Chemistry, 2009
- SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavageProceedings of the National Academy of Sciences, 2009
- Expression Cloning of TMEM16A as a Calcium-Activated Chloride Channel SubunitCell, 2008